Hot Topic
NBR Focus: GMO
Fairfax has made bold moves, says Deutsche Bank, but not enough to staunch "relentless group revenue decline."
Analyst Andrew Anagnostellis left his "hold" recommendation on Fairfax shares, and his target price unchanged at 67c (shares [ASX:FXJ] rose 5c to close at 65c after the restructure
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
NZ$399.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Chris Keall
Tue, 19 Jun 2012
Tue, 19 Jun 2012
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Will Fairfax changes stanch decline? Analyst's verdict
21515